Sonnet Biotherapeutics Holdings Inc. Stock
Currently there is a rather positive sentiment for Sonnet Biotherapeutics Holdings Inc. with 3 Buy predictions and 0 Sell predictions.
With a target price of 18 € there is potential for a 9682.61% increase which would mean more than doubling the current price of 0.18 € for Sonnet Biotherapeutics Holdings Inc..
Our community identified positive and negative aspects for Sonnet Biotherapeutics Holdings Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Sonnet Biotherapeutics Holdings Inc. stock. On the other hand our users think that "Expected dividend yield" could be a problem in the future.
Pros and Cons of Sonnet Biotherapeutics Holdings Inc. in the next few years
Pros
?
M***** P*******
?
B****
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Sonnet Biotherapeutics Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Sonnet Biotherapeutics Holdings Inc. | - | - | - | - | - | - | - |
| Skylark Co Ltd | 3.390% | -3.175% | 5.172% | 22.000% | 26.207% | 69.444% | 40.769% |
| J D Wetherspoon plc | -0.630% | 0.000% | 12.766% | 11.189% | 14.388% | 66.318% | -34.243% |
| SSP Group plc | 2.130% | 10.983% | 28.000% | -11.111% | -3.030% | -25.581% | -45.268% |
Comments
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.
Show more
Ratings data for SONN provided by MarketBeat
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.
Show more
Ratings data for SONN provided by MarketBeat
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) had its price target lowered by analysts at Chardan Capital from $30.00 to $20.00. They now have a "buy" rating on the stock.
Show more
Ratings data for SONN provided by MarketBeat